Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 331 Results
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
April 17, 2025
Palatin Appeals NYSE American Notice of Delisting
April 14, 2025
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
April 10, 2025
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
March 31, 2025
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
March 28, 2025
Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
March 25, 2025
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
February 13, 2025
Page 1 of 34